[ORGANIZATION]
Braveheart Bio Inc.
Featured in 2 tracked stories · first seen
Situations
Iovance Biotherapeutics financial performance and stock rise
2 clusters · 4 sources · last updated
Latest: Iovance Biotherapeutics surges as institutional investors shift Qualcomm and Atkore holdings
Iovance Biotherapeutics experienced significant financial growth and stock market momentum in mid-2026. The company reported second-quarter revenue of approximately $99.3 million, representing a 66% increase from the pre
Braveheart Bio initial public offering
2 clusters · 4 sources · last updated
Latest: Braveheart Bio completes $382M IPO amid insider stock purchases
Braveheart Bio Inc., a biopharmaceutical company focused on therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, initiated its initial public offering on the Nasdaq Global Market. The company u